The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arendse, B.
Right arrow Articles by Brombacher, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arendse, B.
Right arrow Articles by Brombacher, F.
The Journal of Immunology, 2005, 174: 2205-2211.
Copyright © 2005 by The American Association of Immunologists

IL-9 Is a Susceptibility Factor in Leishmania major Infection by Promoting Detrimental Th2/Type 2 Responses1

Berenice Arendse*, Jacques Van Snick{dagger} and Frank Brombacher2,*

* University of Cape Town, Health Science Faculty, Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa; and {dagger} Ludwig Institute for Cancer Research, Brussels, Belgium

IL-9 is a cytokine produced by Th2 cells, induced during Leishmania major infection. Because the role of IL-9 in leishmaniasis is currently unknown, IL-9-deficient mice were generated by immunization with mouse IL-9 coupled to OVA. This produced strong and long-lasting neutralizing anti-IL-9 Abs in vivo. Anti-IL-9 vaccination showed protective effects, because it enabled L. major-infected nonhealer BALB/c mice to better resist to leishmaniasis with doubling the time span until pathological disease progression occurred. Increased resistance was also demonstrated by moderate footpad swelling and histopathology due to reduced parasite burden compared with sham-immunized BALB/c mice. Mechanistically, IL-9 neutralization in BALB/c mice resulted in a reduction of detrimental Th2/type 2 responses with an observed shift toward protective Th1 immune responses. This led to an alteration from alternative to classical macrophage activation with subsequent enhanced killing effector functions, as demonstrated by increased NO production but reduced arginase 1-mediated macrophage responses. Conclusively, the data show that IL-9 is a susceptible factor in leishmaniasis. They further suggest that IL-9 is able to influence Th dichotomy in leishmaniasis by promoting detrimental Th2/type 2 responses in BALB/c mice. The results extend efforts made to generate autoantibodies capable of regulating biological processes, with IL-9 a potential drug target against leishmaniasis.




This article has been cited by other articles:


Home page
J. Exp. Med.Home page
E. E. Forbes, K. Groschwitz, J. P. Abonia, E. B. Brandt, E. Cohen, C. Blanchard, R. Ahrens, L. Seidu, A. McKenzie, R. Strait, et al.
IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity
J. Exp. Med., April 14, 2008; 205(4): 897 - 913.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Steenwinckel, J. Louahed, C. Orabona, F. Huaux, G. Warnier, A. McKenzie, D. Lison, R. Levitt, and J.-C. Renauld
IL-13 Mediates In Vivo IL-9 Activities on Lung Epithelial Cells but Not on Hematopoietic Cells
J. Immunol., March 1, 2007; 178(5): 3244 - 3251.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Holscher, B. Arendse, A. Schwegmann, E. Myburgh, and F. Brombacher
Impairment of Alternative Macrophage Activation Delays Cutaneous Leishmaniasis in Nonhealing BALB/c Mice
J. Immunol., January 15, 2006; 176(2): 1115 - 1121.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. T. M. Roberts, C. B. Stober, A. N McKenzie, and J. M. Blackwell
Interleukin-4 (IL-4) and IL-10 Collude in Vaccine Failure for Novel Exacerbatory Antigens in Murine Leishmania major Infection
Infect. Immun., November 1, 2005; 73(11): 7620 - 7628.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.